• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

KIF11 作为一种潜在的癌症预后标志物,促进儿童肾母细胞瘤的肿瘤发生。

KIF11 as a potential cancer prognostic marker promotes tumorigenesis in children with Wilms tumor.

机构信息

School of Medicine, Nantong University, Nantong, China.

Department of General Surgery, Yancheng Third People's Hospital, Yancheng, China.

出版信息

Pediatr Hematol Oncol. 2022 Mar;39(2):145-157. doi: 10.1080/08880018.2021.1953655. Epub 2021 Aug 11.

DOI:10.1080/08880018.2021.1953655
PMID:34378481
Abstract

Emerging evidence suggests that KIF11 could play a pivotal role in cancer cell proliferation; however, its biological functions and molecular mechanisms in Wilms tumor (WT) cells are largely unknown. The aim of this study was to evaluate the clinical significance and therapeutic potential of KIF11 proteins in WT. KIF11 expression in WT tissues and adjacent nontumor tissues was determined using qRT-PCR, Western blotting, immunohistochemistry (IHC) and bioinformatics. The function of KIF11 protein was determined by its correlation with tumor cell growth, angiogenesis, and apoptosis using IHC and lentiviral vector-mediated KIF11 depletion. KIF11 expression was upregulated in WT tissues and was associated with WT clinical outcomes. Tumor KIF11 expression was significantly associated with the Ki67 proliferation index. CCK-8, flow-cytometric analysis, and Western blotting revealed that KIF11 knockdown significantly inhibited WT cell growth. Functional studies have indicated that increased KIF11 expression is significantly correlated with vascular endothelial growth factor (VEGF) expression and intratumoral microvessel density. We further confirmed that downregulated expression of KIF11 promoted cell apoptosis and significantly increased Bcl-2 and Bax expression. Our findings demonstrate that KIF11 plays a role in promoting the development of human WT and can serve as a potential molecular marker for the treatment of WT.

摘要

新出现的证据表明,KIF11 可能在癌细胞增殖中发挥关键作用;然而,其在Wilms 瘤(WT)细胞中的生物学功能和分子机制在很大程度上仍是未知的。本研究旨在评估 KIF11 蛋白在 WT 中的临床意义和治疗潜力。通过 qRT-PCR、Western blot、免疫组织化学(IHC)和生物信息学检测 WT 组织和相邻非肿瘤组织中的 KIF11 表达。通过 IHC 和慢病毒载体介导的 KIF11 耗竭来确定 KIF11 蛋白的功能,其与肿瘤细胞生长、血管生成和细胞凋亡有关。WT 组织中 KIF11 表达上调,并与 WT 临床结局相关。肿瘤 KIF11 表达与 Ki67 增殖指数显著相关。CCK-8、流式细胞术分析和 Western blot 显示,KIF11 敲低显著抑制 WT 细胞生长。功能研究表明,KIF11 表达增加与血管内皮生长因子(VEGF)表达和肿瘤内微血管密度显著相关。我们进一步证实,下调 KIF11 表达促进细胞凋亡,并显著增加 Bcl-2 和 Bax 表达。我们的研究结果表明,KIF11 在促进人类 WT 的发展中发挥作用,可作为 WT 治疗的潜在分子标志物。

相似文献

1
KIF11 as a potential cancer prognostic marker promotes tumorigenesis in children with Wilms tumor.KIF11 作为一种潜在的癌症预后标志物,促进儿童肾母细胞瘤的肿瘤发生。
Pediatr Hematol Oncol. 2022 Mar;39(2):145-157. doi: 10.1080/08880018.2021.1953655. Epub 2021 Aug 11.
2
MicroRNA-197 Mediates the Overgrowth and Anti-Apoptotic Effects by Downregulating Insulin-Like Growth Factor-Binding Protein-3 During Nephroblastoma Tumorigenesis.微小RNA-197在肾母细胞瘤发生过程中通过下调胰岛素样生长因子结合蛋白-3介导过度生长和抗凋亡作用。
Fetal Pediatr Pathol. 2016;35(5):287-298. doi: 10.1080/15513815.2016.1178360. Epub 2016 May 25.
3
S100A4 mRNA as a prognostic marker and therapeutic target in Wilms tumor (WT).S100A4信使核糖核酸作为肾母细胞瘤(WT)的预后标志物和治疗靶点。
Eur Rev Med Pharmacol Sci. 2014;18(6):817-27.
4
MiR-155-5p exerts tumor-suppressing functions in Wilms tumor by targeting IGF2 via the PI3K signaling pathway.miR-155-5p 通过靶向 IGF2 抑制 PI3K 信号通路发挥抑癌作用,进而抑制肾母细胞瘤的发生发展。
Biomed Pharmacother. 2020 May;125:109880. doi: 10.1016/j.biopha.2020.109880. Epub 2020 Jan 28.
5
miR-483-5p Targets MKNK1 to Suppress Wilms' Tumor Cell Proliferation and Apoptosis In Vitro and In Vivo.miR-483-5p 通过靶向调控 MKNK1 抑制肾母细胞瘤细胞的增殖和凋亡。
Med Sci Monit. 2019 Feb 24;25:1459-1468. doi: 10.12659/MSM.913005.
6
Expression of TCF3 in Wilms' tumor and its regulatory role in kidney tumor cell viability, migration and apoptosis .TCF3 在肾母细胞瘤中的表达及其对肾肿瘤细胞活力、迁移和凋亡的调控作用。
Mol Med Rep. 2021 Sep;24(3). doi: 10.3892/mmr.2021.12281. Epub 2021 Jul 19.
7
KIF11 Promotes Proliferation of Hepatocellular Carcinoma among Patients with Liver Cancers.驱动蛋白家族成员11(KIF11)促进肝癌患者中肝细胞癌的增殖。
Biomed Res Int. 2021 Jan 4;2021:2676745. doi: 10.1155/2021/2676745. eCollection 2021.
8
Effects of MicroRNA-19b on the Proliferation, Apoptosis, and Migration of Wilms' Tumor Cells Via the PTEN/PI3K/AKT Signaling Pathway.微小RNA-19b通过PTEN/PI3K/AKT信号通路对肾母细胞瘤细胞增殖、凋亡及迁移的影响
J Cell Biochem. 2017 Oct;118(10):3424-3434. doi: 10.1002/jcb.25999. Epub 2017 May 30.
9
MiR-200c inhibits proliferation and promotes apoptosis of Wilms tumor cells by regulating akt signaling pathway.miR-200c 通过调节 akt 信号通路抑制肾母细胞瘤细胞的增殖并促进其凋亡。
Eur Rev Med Pharmacol Sci. 2020 Jun;24(12):6623-6631. doi: 10.26355/eurrev_202006_21648.
10
Over-Expression of miR-21 and Lower PTEN Levels in Wilms' Tumor with Aggressive Behavior.具有侵袭性行为的肾母细胞瘤中miR-21的过表达及PTEN水平降低
Tohoku J Exp Med. 2017 May;242(1):43-52. doi: 10.1620/tjem.242.43.

引用本文的文献

1
Functional screening identifies kinesin spindle protein inhibitor filanesib as a potential treatment option for hepatoblastoma.功能筛选确定驱动蛋白纺锤体蛋白抑制剂非那西布为肝母细胞瘤的一种潜在治疗选择。
NPJ Precis Oncol. 2025 Apr 25;9(1):122. doi: 10.1038/s41698-025-00915-8.
2
Mechanisms of against hepatocellular carcinoma elucidated by network pharmacology and experimental validation.通过网络药理学和实验验证阐明的抗肝细胞癌机制
Am J Transl Res. 2025 Feb 15;17(2):1402-1415. doi: 10.62347/VLGD3371. eCollection 2025.
3
Transcriptomic landscape of quiescent and proliferating human corneal stromal fibroblasts.
人角膜基质成纤维细胞静息态和增殖态的转录组图谱
Exp Eye Res. 2024 Nov;248:110073. doi: 10.1016/j.exer.2024.110073. Epub 2024 Sep 5.
4
The relationship between vascular endothelial growth factor expression and the risk of childhood nephroblastoma: systematic review and meta-analysis.血管内皮生长因子表达与儿童肾母细胞瘤风险之间的关系:系统评价与荟萃分析
Transl Pediatr. 2022 Mar;11(3):375-384. doi: 10.21037/tp-21-593.